What the Published Record Actually Reports
There is no established dose of tesamorelin for general use. The compound holds a narrow marketing authorisation in the United States for one specific clinical indication, and every quantitative figure in the peer-reviewed literature comes from trials conducted within that indication. Outside it, no dose has been established in any population, and none is proposed here.
This page collects what the published trials reported: the amounts studied, the populations studied, the routes used, and the citation for each. It is a literature summary for researchers designing in-vitro work, not guidance for administration.
Research use only. Material supplied by AminoCore Research is intended for laboratory research. It is not intended for human or veterinary use, and nothing on this page should be read as a protocol, a recommendation, or clinical guidance.
Amounts Reported in the Clinical Literature
Across the pivotal programme and its follow-on studies, one figure recurs: 2 mg administered subcutaneously, once per day. That figure is not a general-purpose number; it is the amount selected for trials in adults with HIV-associated abdominal fat accumulation, and it should be read as bound to that context.
| Study | Population | Route | Amount reported | Duration | Citation |
|---|---|---|---|---|---|
| Falutz et al., NEJM 2007 | 412 adults, HIV-associated abdominal fat accumulation | Subcutaneous | 2 mg once per day | 26 weeks | PMID 18057338 |
| Falutz et al., AIDS 2008 | Extension cohort from the pivotal trial | Subcutaneous | 2 mg once per day | 52 weeks | PMID 18690162 |
| Stanley et al., Clin Infect Dis 2012 | Adults with excess visceral adiposity, HIV | Subcutaneous | 2 mg once per day | 26–52 weeks | PMID 22495074 |
| Stanley et al., Lancet HIV 2019 | Adults with hepatic steatosis, HIV | Subcutaneous | 2 mg once per day | 12 months | PMID 31611038 |
| Fourman et al., JCI Insight 2020 | Hepatic transcriptomic substudy | Subcutaneous | 2 mg once per day | 12 months | PMID 32701508 |
Two observations follow from the table. First, the amount is strikingly consistent across fifteen years of investigation, which reflects that later studies were built on the pivotal programme's selection rather than re-exploring the range. Second, every entry shares one population. No published trial establishes an amount for a healthy population, for body composition work outside that indication, or for any of the uses commonly discussed in non-clinical settings.
Regulatory Status
Tesamorelin is approved by the United States Food and Drug Administration under the brand name Egrifta, for the reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy. That authorisation is specific and narrow.
What this means in practice: the existence of an approved indication does not extend to other uses. There is no approved indication for athletic performance, general body composition, anti-ageing, or growth hormone optimisation in people without that diagnosis. Material sold for laboratory research is not the approved product, is not manufactured or released to pharmaceutical standards, and carries no clinical authorisation of any kind.
Pharmacokinetics
Tesamorelin clears quickly. Population pharmacokinetic analysis in HIV-infected patients and healthy subjects describes a short elimination half-life on the order of tens of minutes following subcutaneous administration, with the analogue acting on the pituitary in a pulsatile manner consistent with native growth hormone-releasing hormone rather than producing sustained receptor occupancy (González-Sales et al., Clin Pharmacokinet 2015, PMID 25358450).
This is the mechanistic reason the trials used once-daily administration rather than less frequent schedules: the molecule is a secretagogue that provokes an endogenous growth hormone pulse, and the downstream IGF-1 response, not a depot that maintains a level. It also explains why measured effects in the trials accumulated over months rather than weeks — the endpoint was change in visceral adipose tissue, which responds slowly.
Adverse Events Documented in Trials
The pivotal programme and its reviews describe a recognisable adverse event profile. Injection-site reactions were common. Arthralgia, myalgia, peripheral oedema and paraesthesia were reported at higher rates than placebo, consistent with growth hormone axis stimulation. Glucose regulation warrants specific mention: because growth hormone opposes insulin action, the trials tracked glycaemic parameters closely, and reviews of the compound discuss impaired glucose tolerance as a class consideration (Spooner & Horowitz, Ann Pharmacother 2012, PMID 22298602; Dhillon, Drugs 2011, PMID 21668043).
Discontinuation reverses the effect. The long-term extension data show that visceral adipose tissue returns toward baseline once administration stops, which is a material finding for interpreting any reported result (PMID 18690162).
Response is not uniform. An analysis of predictors of response found that a meaningful proportion of participants did not reach the trial's response threshold, and identified baseline characteristics associated with the difference (Mangili et al., PLoS One 2015, PMID 26457580).
Reconstitution and Handling in the Laboratory
These are bench-handling parameters for lyophilised research material, and they are independent of any question of administration.
- Form. Supplied as a lyophilised powder. Store the sealed vial at −20 °C, protected from light.
- Reconstitution. Introduce bacteriostatic water down the vial wall rather than directly onto the powder cake. Do not shake — peptide solutions foam readily, and mechanical agitation promotes aggregation and denaturation.
- Dissolution. Allow the cake to dissolve without agitation. Swirl gently only if needed.
- After reconstitution. Refrigerate at 2–8 °C. Reconstituted peptide solutions have materially shorter working stability than the lyophilised powder.
- Concentration arithmetic. Final concentration is vial mass divided by diluent volume. Our tesamorelin reconstitution calculator performs this arithmetic and converts the result to insulin-syringe units.
For the underlying chemistry of why these handling steps matter, see our overview of lyophilised peptides and temperature effects on peptide stability.
How Tesamorelin Differs From Other Growth Hormone Secretagogues
Tesamorelin is a stabilised analogue of human growth hormone-releasing hormone (hGHRH 1-44), modified with a trans-3-hexenoic acid group on the N-terminal tyrosine that slows enzymatic degradation. It acts at the GHRH receptor.
That places it in a different mechanistic class from the ghrelin-receptor secretagogues such as ipamorelin and the GHRP series, which act at a separate receptor and produce a different endocrine signature. Compounds acting at the two receptors are frequently discussed together because both raise growth hormone, but they are not interchangeable and the published amounts for one say nothing about the other. We cover the distinction in detail in tesamorelin vs ipamorelin.
Reading This Literature Responsibly
Three cautions apply when interpreting the amounts above.
Population is not transferable. Every figure comes from adults with a specific metabolic condition. Extrapolating a number from a diseased population to any other population is not supported by these data.
Approved product is not research material. The trials studied a pharmaceutical product manufactured under clinical standards. Research-grade lyophilised material is a different article with a different purpose.
Absence of a number is information. Where the literature does not report an amount for a given context, that gap is the finding. It should not be filled by inference from a different context.
Further Reading
For the compound's mechanism and full research profile, see the tesamorelin product monograph and our article on tesamorelin and lipid metabolism. For the meaning of the research-use designation itself, see what "for research use only" means.
